Literature DB >> 21629237

Use of FRAX® to target BMD in women <65 years of age.

Eugene McCloskey.   

Abstract

Entities:  

Mesh:

Year:  2011        PMID: 21629237     DOI: 10.1038/nrendo.2011.95

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  5 in total

1.  High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice.

Authors:  W D Leslie; S R Majumdar; L M Lix; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2011-03-02       Impact factor: 4.507

2.  Screening for osteoporosis: U.S. preventive services task force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2011-01-17       Impact factor: 25.391

3.  Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force.

Authors:  Heidi D Nelson; Mark Helfand; Steven H Woolf; Janet D Allan
Journal:  Ann Intern Med       Date:  2002-09-17       Impact factor: 25.391

4.  Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

Authors:  J Compston; A Cooper; C Cooper; R Francis; J A Kanis; D Marsh; E V McCloskey; D M Reid; P Selby; M Wilkins
Journal:  Maturitas       Date:  2009-01-08       Impact factor: 4.342

Review 5.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; N Burlet; C Cooper; P D Delmas; J-Y Reginster; F Borgstrom; R Rizzoli
Journal:  Osteoporos Int       Date:  2008-02-12       Impact factor: 4.507

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.